 |
0 Diseases |  |
8 Trials |
|
8 Trials |  |
181 News |  |
| «123456» |
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo
A phase 2 Study of Patritumab Deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01) (Berlin Hall) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_251;
P1/2, P2
Conclusions HER3-DXd showed early signs of activity and a manageable safety profile in pts with HR+ HER2- ABC. Results on biomarkers analysis will also be presented.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial (Berlin Hall) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_250;
P1
The safety profile was consistent with that previously reported. Additional correlative analysis will be presented on site.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo
HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial (Berlin Hall) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_234;
P1
The association of HER2 IHC and ERBB2 mRNA with CelTIL response will be independently validated in TOT-HER3 Part B. Conclusions Low HER2 IHC, mRNA or CN levels in early-stage HR+/HER2- BC are associated with high response to HER3-DXd. HER3-DXd might be highly active in HR+ BC with very low HER2 levels, thereby offering a new therapeutic paradigm to this subset of patients.
- |||| HER3-DXd (U3-1402) / Daiichi Sankyo
Clinical: Updated activity of HER3-DXd in MBC depending on HER2-low expression. Small numbers, impairing comparisons. Interesting finding: all 12 cases of ILD occurred in patients from Japan, none in patients from the US. https://t.co/3UfMwWmGWR (Twitter) - Mar 19, 2023
- |||| HER3-DXd (U3-1402) / Daiichi Sankyo
Presidential session @JSMO_official. Prof. Hidetoshi Hayashi presented the U31402-A-U102 Study of HER3‑DXd in EGFR-Mutated NSCLC. FREE on-demand access for international audiences! https://t.co/M3njqk44vJ #JSMO2023 #LCSM (Twitter) - Mar 17, 2023
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo
The impact of HER3 dynamics on the efficacy of HER3-DXd, a novel HER3 directed antibody-drug conjugate (Section 19; Poster Board #19) - Mar 14, 2023 - Abstract #AACR2023AACR_6070;
HER3 expression was dynamically changed by HER3-DXd dosing regimen and by RTKi treatment, resulting in a substantial impact on payload release. These findings support our strategy of clinical studies using HER3-DXd after drugs that increase HER3 expression including EGFR TKI and indicate that HER3 dynamics may play a key role in achieving optimal efficacy of HER3-DXd.
- HMBD-501 / Hummingbird Biosci
HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models (Section 13; Poster Board #28) - Mar 14, 2023 - Abstract #AACR2023AACR_4884;
In conclusion, HMBD-501 represents a next generation HER3 targeting ADC that has a potentially best-in-class efficacy and tolerability profile. Our findings strongly support the development of HMBD-501 as a promising candidate in the treatment of HER3 expressing solid tumors.
- DB-1310 / DualityBio
DB-1310, a novel Her3 targeting antibody-drug conjugate, exhibits therapeutic efficacy for solid tumors (Section 25; Poster Board #23) - Mar 14, 2023 - Abstract #AACR2023AACR_4030;
DB-1310 exhibited its efficacy in tumor models both in vitro and in vivo. These studies suggest that DB-1310 as a novel HER3-targeting ADC showed antitumor efficacy for HER3 positive tumors with good safety profile.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, patritumab (U3-1287) / Amgen, Daiichi Sankyo
HERTHENA-Lung02: A randomized Phase 3 study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR tyrosine kinase inhibitor (Section 46; Poster Board #24) - Mar 14, 2023 - Abstract #AACR2023AACR_3693;
P1, P3
Patients are stratified by prior third-generation EGFR TKI treatment (osimertinib vs other), line of prior third-generation EGFR TKI use (first vs second line), region (Asia vs rest of world), and presence of stable brain metastases (yes vs no)...Other secondary endpoints include investigator-assessed progression-free survival, objective response rate, duration of response, clinical benefit rate, disease control rate, time to response (all assessed by investigator and BICR per RECIST 1.1), safety, and patient-reported outcomes. Enrollment began May 2022 and is ongoing, with sites in Asia, Australia, Europe, and North America.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, patritumab (U3-1287) / Amgen, Daiichi Sankyo
Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis (Section 36; Poster Board #9) - Mar 14, 2023 - Abstract #AACR2023AACR_2097;
Background: HER3, a member of the ERBB family of receptor tyrosine kinases that activates multiple oncogenic signaling pathways, is overexpressed in 50-70% of breast cancers (BC). The combination of HER3-DXd plus ATR inhibitors has therapeutic potential for overcoming tamoxifen resistance in HER3+/ER+ BC.
- | HER3-DXd (U3-1402) / Daiichi Sankyo
Journal, Heterogeneity: Quantitative analysis of drug distribution in heterogeneous tissues using dual-stacking capillary electrophoresis-mass spectrometry. (Pubmed Central) - Feb 27, 2023
Our LDMS-CE-MS successfully visualized the attomole-level drug distributions in heterogeneous clinical specimens. This new platform opens a new era of quantitative pharmacokinetic analysis, facilitating drug discovery and development.
- || HER3-DXd (U3-1402) / Daiichi Sankyo
Buenísimo. Que alegría. Yo estoy en el Ensayo clínico Fase II HERTHENA con patritumab deruxtecan y después de 15 meses de tratamiento, y 46 meses desde diagnóstico ( previos tratamientos con gefi, osi y prasel ) ahí seguimos!!!. QUE VIVA LA INVESTIGACIÓN!!!. (Twitter) - Feb 23, 2023
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment closed, Metastases: U31402-A-U102: HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 16, 2023
P1, N=271, Active, not recruiting, Sponsor: Daiichi Sankyo, Inc.
This new platform opens a new era of quantitative pharmacokinetic analysis, facilitating drug discovery and development. Recruiting --> Active, not recruiting
- ||||| HER3-DXd (U3-1402) / Daiichi Sankyo
Clinical: ❶/❽ 📢 Very happy to share, [specially today] our 🆅🅰🅻🅴🅽🆃🅸🅽🅴-Ph.2 trial of neoadjuvant HER3-DXd w/ or w/out ET in high-risk HR+/HER2- #breastcancer patients 👨⚕️👩⚕️PIs: @prat_aleix @MOliveira_MD in collaboration with @DaiichiSankyoES 👇 @TomasPascualMD (Twitter) - Feb 14, 2023
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Trial initiation date: PARAMETer: A Window of Opportunity Study of Patritumab Deruxtecan in Patients with Brain Metastases (clinicaltrials.gov) - Jan 20, 2023
P1, N=15, Not yet recruiting, Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Recruiting --> Active, not recruiting Initiation date: Dec 2022 --> Mar 2023
- || HER3-DXd (U3-1402) / Daiichi Sankyo
Patritumab deruxtecan could be an interesting alternative considering the Her2 coamplification and the results in MBC and EGFR+ LUAD. However, in absence of the Patri, I would try CBP/Pem and low doses of Afa, if there is no brain involvement. If there is, I would keep the Osi. (Twitter) - Jan 13, 2023
- || HER3-DXd (U3-1402) / Daiichi Sankyo, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, telisotuzumab vedotin (ABBV-399) / AbbVie
Review, Journal: Antibody-drug conjugates in lung cancer: dawn of a new era? (Pubmed Central) - Jan 12, 2023
In this review, we discuss the structure and mechanism of action of ADCs, including insights from pre-clinical work; we summarize the ADCs' recent progress in lung cancer, describe toxicity profiles of ADCs, and explore strategies designed to enhance ADC potency and overcome resistance. In addition, we discuss novel ADC strategies of interest in lung cancer, including non-cytotoxic payloads, such as immunomodulatory and anti-apoptotic agents.
- HER3-DXd (U3-1402) / Daiichi Sankyo, Dato-DXd (DS-1062a) / Daiichi Sankyo, AstraZeneca
Exploring Daiichi Sankyo’sExtensive ADC Clinical Programme,Including HER3-DXd & Dato-DXd () - Jan 2, 2023 - Abstract #ADCLondon2023ADC_London_143;
In addition, we discuss novel ADC strategies of interest in lung cancer, including non-cytotoxic payloads, such as immunomodulatory and anti-apoptotic agents. • HER3-DXd is an antibody-drug conjugate targeting HER-3 in Phase III trials • Dato-DXd is a Phase III ADC targeting HER-2 • Exploring the clinical updates of- DSI’s antibody-drug conjugate development pipeline
- | patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Trial completion date, Metastases: U31402-A-J101: Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 12, 2022
P1/2, N=184, Active, not recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
• HER3-DXd is an antibody-drug conjugate targeting HER-3 in Phase III trials • Dato-DXd is a Phase III ADC targeting HER-2 • Exploring the clinical updates of- DSI’s antibody-drug conjugate development pipeline Trial completion date: Dec 2022 --> Dec 2023
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
@_SOLTI TOTHER3 — Molecular determinants of response to patritumab deruxtecan in early-stage HR+/HER2- breast cancer @fara_bm @OlgaMartnezSez1 Trial led by @MOliveira_MD @prat_aleix (Twitter) - Dec 8, 2022
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment open: NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (clinicaltrials.gov) - Nov 30, 2022
P2, N=120, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Trial completion date: Dec 2022 --> Dec 2023 Not yet recruiting --> Recruiting
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
P5-02-31 Thursday @SABCSSanAntonio Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial Presenter: @fara_bm (Twitter) - Nov 27, 2022
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
New P1 trial: PARAMETer: A Window of Opportunity Study of Patritumab Deruxtecan in Patients with Brain Metastases (clinicaltrials.gov) - Nov 17, 2022
P1, N=15, Not yet recruiting, Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na (clinicaltrials.gov) - Nov 2, 2022
P2, N=360, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting N=270 --> 360
- ||||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM (Twitter) - Oct 29, 2022
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Rybrevant (amivantamab-vmjw) / Genmab, J&J, Tagrisso (osimertinib) / AstraZeneca
Review, Journal, IO biomarker: New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. (Pubmed Central) - Oct 28, 2022
In this review, we outline our proposed approach to current clinical practice for patients with EGFR mutant, osimertinib-resistant NSCLC which includes the following potential strategies: - Continuation of osimertinib beyond progression following local ablative treatment of oligoprogressive disease, - Tissue rebiopsy of progressive site and possibly concurrent liquid biopsy to evaluate for mechanism of resistance utilizing comprehensive genomic profiling, -Discussion at a molecular tumor board for assessment for enrollment in clinical trials/expanded access program if available with innovative drugs or possible off-label use of available targeted agents, based on the results of molecular profiling, -If no mechanism of resistance identified, administration of platinum-based chemotherapy with antiangiogenic agents. The role of immunotherapy will also be addressed given the uncertain benefit.
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
13) Also 🆕 during #ESMO22: a trial in progress with another #ADC in rapid development for #NSCLC, in particular in #EGFR-resistant setting: #Patritumab_Deruxtecan (#HER3_DXd) (Twitter) - Oct 18, 2022
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial (Hall 1) - Oct 10, 2022 - Abstract #SABCS2022SABCS_1236;
P1
TP53 mutations, immune-related genes, and DNA/RNA-based phenotypic signatures tracking Basal- or Luminal A-related biology such as the DNA-based RB-LOH score or the endocrine sensitivity score (Scorr_IE_Correlation) are associated with CelTIL changes in response to HER3-DXd in HR+/HER2- breast cancer. Further RNA- and DNA-based analyses will be evaluated.
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
New P2 trial: NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (clinicaltrials.gov) - Oct 6, 2022
P2, N=120, Not yet recruiting, Sponsor: SOLTI Breast Cancer Research Group
- |||||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Clinical: 8/17 #TumorBoardTuesday ✨HERTHENA-Lung 1 trial✨ 🔹HER3 antibody-drug conjugate (ADC) patritumab deruxtecan (DXd) tested in EGFRm+ pts post-osi 🔹ORR: 39% 🔹median PFS 8.2 m 💥no relationship to HER3 expression💥 📚https://t.co/rApQ2GJmBH (Twitter) - Oct 3, 2022
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
https://t.co/id1APCulbd Patritumab deruxtecan also with activity in non-EGFR mutated NSCLC. I suspect a lot of bystander effect with these ADCs (including those targeting TROP2). Mutation presence or level of expression (HER3 or TROP2) seems to be less important…so far. (Twitter) - Oct 3, 2022
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations (Ballroom FGH) - Sep 14, 2022 - Abstract #IASLCNACLC2022IASLC_NACLC_131;
P1
These data extend previous findings in patients with EGFR m NSCLC and demonstrate promising clinical activity in patients with NSCLC harboring genomic alterations other than EGFR m and in those without identified driver genomic alterations. The overall safety profile was similar to that previously reported in patients with EGFR m NSCLC.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, patritumab (U3-1287) / Amgen, Daiichi Sankyo
HERTHENA-Lung02: A Randomized Phase 3 Study of Patritumab Deruxtecan vs Platinum-Based Chemotherapy in Locally Advanced or Metastatic EGFR-Mutated NSCLC After Progression with a Third-Generation EGFR TKI (Ballroom FGH) - Sep 14, 2022 - Abstract #IASLCNACLC2022IASLC_NACLC_82;
P1, P3
Pts are stratified by prior 3rd-gen EGFR TKI treatment (osimertinib vs other), line of prior 3rd-gen EGFR TKI use (first vs second line), region (Asia vs rest of world), and presence of stable brain metastases (yes vs no)...Enrollment began May 2022 and is ongoing, with sites in the US, Canada, EU, Asia, and Australia. This trial in progress was previously presented at ESMO 2022.
- An exatecan derivative based linker-payload platform leads to ADC products with promising anti-tumor efficacy and potential low interstitial lung disease (ILD) risk (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_387;
P1/2
Currently, DB-1303 is under clinical evaluation (ClinicalTrials.gov Identifier: NCT05150691). No
- || patritumab deruxtecan (U3-1402) / Daiichi Sankyo
PK/PD data, Journal: Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors. (Pubmed Central) - Sep 3, 2022
Effects of these covariates on the exposure metrics were generally mild and did not require dose adjustment for subpopulations in subsequent development. Further PK characterization for patritumab deruxtecan will evolve with emerging data.
- | patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Certainly one of the best therapeutic option… Waiting for data with patritumab deruxtecan 😉🤔 (Twitter) - Aug 19, 2022
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Clinical, Video: In this video Drs. @JackWestMD , @DrJNaidoo , and @GlopesMd examine the use of Patritumab Deruxtecan in patients without particular mutations. For more, please visit https://t.co/3VETMT8eM4. To join the conversation, visit https://t.co/0YNIfY6pwZ via @YouTube (Twitter) - Aug 16, 2022
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Biomarker: Ami/Laze in EGFR-resistant is under development, as #biomarker agnostic approach, thought data on MET/EGFR acquired resit are encouraging. MARIPOSA-2 & Paloma-3 will be the key to understand if the biomarker agnostic way, could be ready or not, as well as HER3-DXd #LCSM (1) (Twitter) - Aug 12, 2022
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, patritumab (U3-1287) / Amgen, Daiichi Sankyo
HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2914;
P1, P3
Pts are stratified by prior 3rd-gen EGFR TKI treatment (osimertinib vs other), line of prior 3rd-gen EGFR TKI use (first vs second line), region (Asia vs rest of world), and presence of stable brain metastases (yes vs no)...Other secondary endpoints include investigator-assessed PFS, objective response rate, duration of response, clinical benefit rate, disease control rate, time to response (all per BICR per RECIST v1.1), safety, and patient-reported outcomes. Enrollment into the trial is starting in Q2 2022.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, patritumab (U3-1287) / Amgen, Daiichi Sankyo
Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2158;
P1
The primary objective of cohort 4 is to evaluate the PK of this formulation during the first treatment cycle. Secondary objectives include the evaluation of PK, safety, tolerability, immunogenicity, and efficacy.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo
SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_1913;
P1
The primary objective of the part A was to evaluate the mean change in the CelTIL score (Nuciforo P., Annals Oncol 2018) between pre- and post-treatment tumor samples. Secondary objectives in the overall trial population and in part B include: variation in CelTIL score between paired tumor samples; overall response rate at C1D21; correlation between CelTIL change and baseline expression of ERBB3 and HER3 IHC; ERBB3 and HER3 dynamics; CelTIL variation across PAM50 subtypes; safety; and additional pharmacokinetic, genomic and circulating biomarkers.
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Next-generation sequencing: We’re in the ADC era! Saci, T-DXd, and soon Dato-DXd, HER3-DXd… and then, who knows, NGS may open the door to chemo-free approaches… TMB-high is not uncommon in MBC, as shown by @DrRBarroso among others, and can predict response to IO even in late lines! (Twitter) - Jul 19, 2022
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
Enrollment open, Metastases: U31402-A-U102: HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 8, 2022
P1, N=264, Recruiting, Sponsor: Daiichi Sankyo, Inc.
Secondary objectives in the overall trial population and in part B include: variation in CelTIL score between paired tumor samples; overall response rate at C1D21; correlation between CelTIL change and baseline expression of ERBB3 and HER3 IHC; ERBB3 and HER3 dynamics; CelTIL variation across PAM50 subtypes; safety; and additional pharmacokinetic, genomic and circulating biomarkers. Active, not recruiting --> Recruiting
- ||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Clinical: Patritumab Deruxtecan Induces Clinical Activity in NSCLC Regardless of Identified Driver Genomic Alterations https://t.co/tnjeeFkeCO via @onclive (Twitter) - Jul 7, 2022
- ||||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Clinical, P2 data: NCT04699630, A Phase II Study of U3-1402 in Patients With Metastatic Breast Cancer (Twitter) - Jun 30, 2022
P2
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Identification of biomarkers of response to a novel HER3-directed antibody drug conjugate (ADC) using breast cancer (BC) patient-derived xenografts (PDX) models (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_847;
P1, P1/2
TP53-mutant, basal-like PDX models were more likely to show long-term responses to HER3-DXd than luminal B PDX models. Compared to irinotecan, HER3-DXd induced improved antitumor activity inducing higher and persistent levels of S-phase DNA damage.
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
#TumorBoardTuesday HER3 is also a🎯in Lung Ca ✅Dr. Steur👨🏫Ph1 trial of Patritumab deruxtecan in NSCLC 😮BUT the predictor was NOT⬆️HER3 ➡️It was a driver🧬alteration 👉e.g. K/NRAS/EGFR/ROS/ALK ➡️ORR in the driver group = 35% 🔎Abstract 9017 AND - several F/U trials in Lung Ca (Twitter) - Jun 21, 2022
- |||||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Clinical: #TumorBoardTuesday #4⃣ 👇HER3 is a legitimate target ✅Ian E. Krop🧑🏫a Ph1/2 trial of patritumab deruxtecan, a HER3-directed ADC in pts with HER3 expressing Breast Ca 👏Out of 113 patients, the ORR was 30% 🔎Abstract # 1002 🤔I don't see a follow up Ph2 or Ph3 study though? (Twitter) - Jun 21, 2022
- |||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Patritumab deruxtecan (HER3 ADC) in metastatic breast cancer #ASCO22 (Twitter) - Jun 6, 2022
- ||||| patritumab deruxtecan (U3-1402) / Daiichi Sankyo
Clinical: #ASCO22 Patritumab deruxtecan (HER3-DXd) in #EGFR wild type NSCLC from Dr. @ConorSteuerMD showed some efficacy - RR 29% and mPFS 10.8m in driver+ NSCLC and RR 27% and mPFS 4.2m - looking forward to confirmatory studies. (Twitter) - Jun 6, 2022